0001209191-21-028030.txt : 20210422 0001209191-21-028030.hdr.sgml : 20210422 20210422195712 ACCESSION NUMBER: 0001209191-21-028030 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210420 FILED AS OF DATE: 20210422 DATE AS OF CHANGE: 20210422 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gibson Christopher CENTRAL INDEX KEY: 0001856369 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 21846364 MAIL ADDRESS: STREET 1: C/O RECURSION PHARMACEUTICALS STREET 2: 41 S. RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001601830 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464099738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: (385) 269-0203 MAIL ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER COMPANY: FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC DATE OF NAME CHANGE: 20140305 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-20 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001856369 Gibson Christopher C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 1 1 0 0 Chief Executive Officer Common Stock 2021-04-20 4 C 0 55383 A 9317883 D Common Stock 2021-04-20 4 J 0 9317883 D 0 D Class B Common Stock 2021-04-20 4 J 0 9317883 A 9317883 D Common Stock 2021-04-20 4 J 0 150000 D 0 I By Gibson Family Trust Class B Common Stock 2021-04-20 4 J 0 150000 A 150000 I By Gibson Family Trust Serie A Preferred Stock 2021-04-20 4 C 0 22698 0.00 D Common Stock 22698 0 D Series A-1 Preferred Stock 2021-04-20 4 C 0 32685 0.00 D Common Stock 32685 0 D Stock Option (Right to Buy) 2.47 2021-04-20 4 C 0 1500000 0.00 D 2030-12-30 Common Stock 1500000 0 D Stock Option (Right to Buy) 2.47 2021-04-20 4 C 0 1500000 0.00 A 2030-12-30 Class B Common Stock 1500000 1500000 D Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date. One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. /s/ Christopher Gibson 2021-04-22